SciELO - Scientific Electronic Library Online

vol.80 número4Deterioro cognitivo por quimioterapia adyuvante en pacientes con cáncer de mama: Una problemática por definir en el Perú¿Realmente existe una “epidemia de depresión”? índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO


Revista de Neuro-Psiquiatría

versión impresa ISSN 0034-8597


CASTRO-SUAREZ, Sheila; CAPARO-ZAMALLOA, César  y  MEZA-VEGA, María. Myasthenia gravis. Rev Neuropsiquiatr [online]. 2017, vol.80, n.4, pp.247-260. ISSN 0034-8597.

Myasthenia gravis (MG) is an autoimmune disease, characterized by fatigue and localized or generalized muscle weakness, with proximal predominance and fluctuating course; these symptoms stem from the post-synaptic blockade of neuromuscular transmission by antibodies against anti-acetylcholine antibodies and other post-synaptic membrane proteins. The incidence is 8 to 10 cases per million people, and the prevalence of 150 to 250 cases per million; however these figures vary in the different populations studied. The diagnosis of MG is based on the clinical manifestations and positive results of tests such as specific antibodies, neurophysiological tests or therapeutic interventions. The search for associated pathologies should be an important component of the evaluation. The treatment is based on three pillars: use of acetylcholinesterase inhibitors (pyridostigmine), immunotherapy (corticosteroids or immunosuppressants / immunomodulators) and surgical management (thymectomy).

Palabras clave : Myasthenia gravis; neuromuscular junction; thymoma.

        · resumen en Español     · texto en Español     · Español ( pdf )


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons